Effect of Genetic Variants in MATE1 and OCT3 on the Pharmacodynamics of Metformin in African Americans
Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
The current study is part of a large multi-investigator grant to look at the pharmacogenetics
of a number of membrane transporters. The investigators will study individuals with
particular genotypes of the human organic cation transporter, (hOCT3), and the multidrug and
toxin extrusion transporter, MATE1 to test the hypothesis that genetic variation in hOCT3 and
hMATE1 are associated with variation in the pharmacokinetics and/or pharmacodynamics of the
antidiabetic agent, metformin.